NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 42 versions: 10 with changes below, 32 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 3 → 7 locations
- Minor Study sites: 4 to 7
- Minor Trial sites expanded: 0 → 3 locations
- Notable Primary endpoint(s) modified
- Study sites: 2 to 3
- Notable Primary endpoints: 3 to 2
- Secondary endpoints revised (5)
- Study description shortened, about 1 word
- Minor Study sites: 1 to 2
Notable Recruitment opened Show 4 more changesShow less
- Start date pushed from Oct 28, 2026 to Jun 25, 2027
- Eligibility criteria expanded, about 135 words
- Study sites: 0 to 1
- Secondary endpoints: details revised at 3 of 5 entries
- Notable Start date: Jul 30, 2026 to Oct 28, 2026v34
- Notable Start date: May 1, 2026 to Jul 30, 2026v32
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.
Patients receive cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.
Patients receive iberdomide PO, via NG-tube, or via G-tube QD on days 1-14 or 1-21, as determined in phase 1, cyclophosphamide IV over 15-30 minutes on days 1-5, topotecan IV over 30 minutes on days 1-5, dinutuximab IV over 10 hours on days 2-5, and sargramostim SC or IV over 2 hours starting on day 6 or 7 and continuing for a minimum of 7 doses until ANC is ≥ 1500/μL after the expected nadir or until day 21 of each cycle. Cycles repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo ECHO or MUGA, bone marrow aspiration and biopsy, CT or MRI, and 123I-MIBG scans or FDG-PET throughout the study. Patients also undergo blood sample collection on study.
Procedures: Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan
Drugs: Cyclophosphamide, Iberdomide, Topotecan
Biologicals: Dinutuximab, Sargramostim
Radiation: Nuclear Radiology Imaging Procedure
Sites
8 sites in 1 country